
Expanded Recommendation for GSK’s AREXVY Vaccine Targets Adults at Higher Risk for Severe RSV
PHILADELPHIA, PA — The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 50-59 who …
Expanded Recommendation for GSK’s AREXVY Vaccine Targets Adults at Higher Risk for Severe RSV Read More